CA2698859A1 - Multiple analyte diagnostic readout - Google Patents

Multiple analyte diagnostic readout Download PDF

Info

Publication number
CA2698859A1
CA2698859A1 CA2698859A CA2698859A CA2698859A1 CA 2698859 A1 CA2698859 A1 CA 2698859A1 CA 2698859 A CA2698859 A CA 2698859A CA 2698859 A CA2698859 A CA 2698859A CA 2698859 A1 CA2698859 A1 CA 2698859A1
Authority
CA
Canada
Prior art keywords
biomarkers
patient
diagnostic
protein
binary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2698859A
Other languages
English (en)
French (fr)
Inventor
Anthony Shuber
Eugene Chiu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHYSICIANS CHOICE LABORATORY SERVICES LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2698859A1 publication Critical patent/CA2698859A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2698859A 2007-09-14 2008-09-12 Multiple analyte diagnostic readout Abandoned CA2698859A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97250707P 2007-09-14 2007-09-14
US60/972,507 2007-09-14
US12/034,698 2008-02-21
US12/034,698 US20090075266A1 (en) 2007-09-14 2008-02-21 Multiple analyte diagnostic readout
PCT/US2008/076193 WO2009036288A1 (en) 2007-09-14 2008-09-12 Multiple analyte diagnostic readout

Publications (1)

Publication Number Publication Date
CA2698859A1 true CA2698859A1 (en) 2009-03-19

Family

ID=40452512

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2698859A Abandoned CA2698859A1 (en) 2007-09-14 2008-09-12 Multiple analyte diagnostic readout

Country Status (6)

Country Link
US (1) US20090075266A1 (https=)
EP (1) EP2198295A4 (https=)
JP (1) JP2010539490A (https=)
CN (1) CN101878426A (https=)
CA (1) CA2698859A1 (https=)
WO (1) WO2009036288A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
KR20090128474A (ko) * 2007-04-13 2009-12-15 브리스톨-마이어스 스큅 컴퍼니 혈관 내피 성장인자 수용체-2 조절제에 대한 감수성을 판정하기 위한 방법 및 바이오마커
US20090029372A1 (en) * 2007-05-14 2009-01-29 Kobenhavns Universitet Adam12 as a biomarker for bladder cancer
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
WO2010101793A2 (en) * 2009-03-06 2010-09-10 University Of South Alabama Methods and compositions for the diagnosis, prognosis and treatment of cancer
JP5451552B2 (ja) * 2010-08-09 2014-03-26 オリンパス株式会社 顕微鏡システム、標本観察方法およびプログラム
ES2656150T3 (es) * 2011-11-14 2018-02-23 Universitätsklinikum Jena Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
JP6250351B2 (ja) * 2013-09-30 2017-12-20 シスメックス株式会社 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
AR107786A1 (es) * 2016-03-02 2018-06-06 Idexx Lab Inc Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
WO2018187311A1 (en) * 2017-04-03 2018-10-11 Biodetego Llc Biomarkers and methods of using same
GB201810571D0 (en) * 2018-06-27 2018-08-15 Cs Genetics Ltd Reagents and methods for the analysis of circulating microparticles
US20210325380A1 (en) * 2020-04-20 2021-10-21 EnLiSense, LLC Disease diagnostics using a multi-configurable sensing array
CN116930498B (zh) * 2023-08-29 2023-12-12 中国人民解放军军事科学院军事医学研究院 一种原发性肝细胞癌切除术后复发风险预测试剂盒及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
US6566101B1 (en) * 1997-06-16 2003-05-20 Anthony P. Shuber Primer extension methods for detecting nucleic acids
US20040219509A1 (en) * 2001-08-20 2004-11-04 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
JP3771502B2 (ja) * 2002-02-14 2006-04-26 国立大学法人 新潟大学 精神分裂病により発現量が変化する遺伝子を規定する核酸を解析する方法
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
BRPI0607753A2 (pt) * 2005-02-16 2009-10-06 Wyeth Corp método para prever um efeito clìnico em resposta a um tratamento de uma leucemia; método para prever um efeito clìnico de uma leucemia; método para selecionar um tratamento para um paciente com leucemia; método para o diagnóstico ou monitoramento de ocorrência, desenvolvimento, progressão ou tratamento de uma leucemia; arranjo para uso num método para prever um efeito clìnico para um paciente aml; arranjo para uso num método de diagnóstico de aml; meio legìvel por computador; kit para o prognóstico de aml
EP1855727A2 (en) * 2005-02-17 2007-11-21 Dana-Farber Cancer Institute, Inc. Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
CA2605143A1 (en) * 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
WO2007050706A2 (en) * 2005-10-27 2007-05-03 University Of Missouri-Columbia Dna methylation biomarkers in lymphoid and hematopoietic malignancies
US9347945B2 (en) * 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
EP1969363B1 (en) * 2005-12-22 2016-11-30 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US20070255113A1 (en) * 2006-05-01 2007-11-01 Grimes F R Methods and apparatus for identifying disease status using biomarkers
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods

Also Published As

Publication number Publication date
US20090075266A1 (en) 2009-03-19
JP2010539490A (ja) 2010-12-16
WO2009036288A1 (en) 2009-03-19
CN101878426A (zh) 2010-11-03
EP2198295A1 (en) 2010-06-23
EP2198295A4 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
US20090075266A1 (en) Multiple analyte diagnostic readout
US20090047694A1 (en) Clinical Intervention Directed Diagnostic Methods
US20250362295A1 (en) Marker combinations for diagnosing infections and methods of use thereof
CN113396332B (zh) 评价妊娠进展和早产流产以进行临床干预的方法及其应用
US9080206B2 (en) Detection of nucleic acids and proteins
US20120178100A1 (en) Serum Markers Predicting Clinical Response to Anti-TNF Alpha Antibodies in Patients with Psoriatic Arthritis
Hughes et al. Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data
US20190331683A1 (en) Biomarkers of Rapid Progression in Advanced Non-Small Cell Lung Cancer
WO2015157557A1 (en) Methods of diagnosing pancreatic cancer and methods related thereto
EP3133399B1 (en) Chronic kidney disease biomarker
US20190204316A1 (en) Biomarker signatures for lyme disease and methods of use thereof
EP2126562B1 (en) Clinical intervention directed diagnostic methods
US20220390466A1 (en) Biomarkers of early osteoarthritis
CN113302495B (zh) 膀胱癌的检测
US20190033310A1 (en) Biomarker signatures for lyme disease differentiation and methods of use thereof
EP3325972A1 (en) Biomarker combinations for prostate disease
KR102450582B1 (ko) 바이오마커의 추출방법, 췌장암 진단용 바이오마커 및 이를 이용한 췌장암의 진단 방법
HK1138376B (en) Clinical intervention directed diagnostic methods
JP2024145760A (ja) 慢性子宮内膜炎の診断マーカー及び診断用検査キット
Lauffenburger Changes in concentrations of cervicovaginal immune mediators across the menstrual cycle: a systematic review and meta-analysis of individual patient data
CN116246775A (zh) 冠状动脉扩张症的诊断系统、装置

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130912

FZDE Discontinued

Effective date: 20170515